Jochen H. Lorch

TL;DR: Treatment with avelumab was associated with durable responses, most of which are still ongoing, and was well tolerated; hence, a Velumab represents a new therapeutic option for advanced Merkel cell carcinoma.

TL;DR: Although survival results were good in both groups there was no difference noted between those patients treated with induction chemotherapy followed by chemoradiotherapy and those who received chemoradotherapy alone, and the addition of induction chemotherapy remains an appropriate approach for advanced disease with high risk for local or distant failure.

TL;DR: It is shown that short-term exposure to small-molecule inhibitors of cyclin-dependent kinases 4 and 6 significantly enhances T- cell activation, contributing to antitumor effects in vivo, due in part to the derepression of NFAT family proteins and their target genes, critical regulators of T-cell function.

TL;DR: HPV+ OPC has a different biology compared with HPV- OPC; 5-year OS, PFS, and local-regional control are unprecedented; these results support the possibility of selectively reducing therapy and long-term morbidity in HPV+ O PC while preserving survival and approaching HPV- disease with more aggressive treatment.

TL;DR: In this phase 1-2 trial, selpercatinib showed durable efficacy with mainly low-grade toxic effects in patients with medullary thyroid cancer with and without previous vandetanib or cabozantinib treatment.